Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
NCT03488251 · Molecular Templates, Inc. · PHASE2 · terminated · last registry update 2022-08-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Molecular Templates, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MS4A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-08-14Phase 3 first posted: University of Birmingham, Odronextamab + Loncastuximab tesirine (NCT05991388)
- 2023-07-18Results posted on the registry: Mayo Clinic, Rituximab (NCT02320292)
- 2023-07-03Phase 3 first posted: Fondazione Italiana Linfomi - ETS, a drug against MS4A1 (NCT05929222)
- 2023-05-26Phase 3 first posted: TG Therapeutics, Inc., Ublituximab + Placebo (NCT05877963)
- 2023-03-28Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, single infusion of Rituximab + single infusion of Obinutuzumab (NCT05786768)
- 2023-03-07Phase 3 first posted: Rennes University Hospital, Perfusion of treatment Rituximab + Perfusion of treatment Ocrelizumab (NCT05758831)
- 2023-01-10Results posted on the registry: Acerta Pharma BV, Acalabrutinib + Obinutuzumab (NCT02475681)
- 2022-11-25Phase 3 first posted: Hoffmann-La Roche, Obinutuzumab + MMF (NCT05627557)
- 2022-10-13Phase 3 first posted: Genmab, Epcoritamab + Cyclophosphamide (NCT05578976)
- 2022-06-08Phase 3 first posted: Genmab, Epcoritamab + Rituximab (NCT05409066)
- 2022-03-28Results posted on the registry: Janssen Research & Development, LLC, Ibrutinib + Venetoclax (NCT03462719)
- 2022-03-07Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab (NCT05269004)
- 2022-02-10Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab IV + Ocrelizumab SC (NCT05232825)
- 2022-01-19Phase 3 first posted: German CLL Study Group, Obinutuzumab + Venetoclax (NCT05197192)
- 2021-12-29Phase 3 first posted: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab vedotin (NCT05171647)
- 2021-11-17Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab + Fingolimod (NCT05123703)
- 2021-10-29Phase 3 first posted: BeOne Medicines, Zanubrutinib + Rituximab (NCT05100862)
- 2021-09-27Phase 3 first posted: AstraZeneca, Acalabrutinib + Venetoclax (NCT05057494)
- 2021-09-27Phase 3 first posted: Fondazione Italiana Linfomi - ETS, Immunochemotherapy regimen: Rituximab-bendamustine (Arm A) + Immunochemotherapy regimen: Rituximab-bendamustine (Arm B) (NCT05058404)
- 2021-09-16Phase 3 first posted: Heidelberg University, Standard + Experimental (NCT05045664)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision